Business Context and Reporting Period
This Form 8-K Current Report was filed by Oramed Pharmaceuticals Inc. on July 14, 2021, covering events occurring on July 14 and July 15, 2021. The company is a Delaware corporation with its principal executive offices in New York, New York. Its common stock trades on The Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.
Key Financial Metrics and Capital Activities
The filing details a new equity financing arrangement rather than operational financial results.
- New Equity Facility: Entered into an Equity Distribution Agreement with Canaccord Genuity LLC to sell up to $100,000,000 of common stock.
- Recent Proceeds: Under the previous agreement (June 16, 2021), the company sold 837,419 shares for gross proceeds of $10,987,000 between June 16 and July 14, 2021.
- Remaining Capacity: Approximately $17,013,000 remains available under the prior agreement, in addition to the new $100 million facility.
- Compensation: The company will pay a cash commission of 3.0% of gross proceeds to the agent.
- Operational Metrics: The filing text does not provide revenue, profit, cash flow, margins, or debt figures.
Material Changes and Corporate Governance
The company executed significant changes to its capital structure and governance bylaws:
- Bylaw Amendment: Adopted Second Amended and Restated By-laws to clarify voting standards. All matters at stockholder meetings will now be decided by a majority of shares present in person or by proxy, resolving ambiguity regarding broker non-votes.
- Legal Settlement: The bylaw change was adopted to settle a complaint filed in the Court of Chancery of Delaware regarding voting standards at the 2019 and 2020 annual meetings.
- Shareholder Ratification: The Board plans to re-submit proposals from the 2019 and 2020 annual meetings for ratification at the 2021 Annual Meeting. These include the approval of the 2019 Incentive Plan, its 2020 amendment, and the re-election of seven directors.
Outlook, Risks, and Contingencies
Management commentary and risks are centered on the potential invalidation of prior corporate actions:
- Contingency Risk: If the proposed ratification of the 2019 and 2020 approvals is not passed by a majority vote at the 2021 Annual Meeting, the 2019 Stock Incentive Plan and its amendments will be deemed void. Consequently, any awards granted under these plans must be rescinded.
- Director Validity: Failure to ratify would also void the election of the seven directors listed in the filing, requiring the company to assess the validity of actions taken by these directors since their election.
- Financing Uncertainty: There is no assurance that the company will sell any shares under the new Equity Distribution Agreement, nor is there assurance regarding the price, amount, or timing of such sales.
Investor Verification Checklist
- Verify the status of the pending ratification vote for the 2019 and 2020 stockholder approvals at the upcoming 2021 Annual Meeting.
- Confirm the total number of shares outstanding and the dilution impact of the new $100 million equity distribution facility.
- Review the full text of the Second Amended and Restated By-laws (Exhibit 3.1) to understand the specific voting mechanics.
- Monitor future filings for the actual execution of share sales under the new Canaccord Genuity agreement.
- Check for any updates regarding the Court of Chancery complaint to ensure the settlement is fully finalized.